Financière de Tubize SA Ret. on equity
What is the Ret. on equity of Financière de Tubize SA?
The Ret. on equity of Financière de Tubize SA is 9.88%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with ret. on equity similar to Financière de Tubize SA
- Genesys International has Ret. on equity of 9.87%
- Generix SA has Ret. on equity of 9.87%
- ACC has Ret. on equity of 9.87%
- Navigator Global Investments has Ret. on equity of 9.87%
- Boiron SA has Ret. on equity of 9.87%
- Boiron SA has Ret. on equity of 9.87%
- Financière de Tubize SA has Ret. on equity of 9.88%
- Sical Logistics has Ret. on equity of 9.88%
- B.L. Kashyap and Sons has Ret. on equity of 9.89%
- Xilam Animation SA has Ret. on equity of 9.89%
- Xilam Animation has Ret. on equity of 9.89%
- Gillanders Arbuthnot and has Ret. on equity of 9.89%
- Sodifrance SA has Ret. on equity of 9.89%